Ascrinvacumab is under clinical development by Kintor Pharmaceutical and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC). According to GlobalData, Phase II drugs for Metastatic Hepatocellular Carcinoma (HCC) have a 23% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ascrinvacumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ascrinvacumab overview

Ascrinvacumab (PF-03446962) is under development for the treatment of advanced solid tumors including metastatic hepatocellular carcinoma, solid tumor and liver cancer. It is also under development for the treatment of ESCC, urothelial cancer, HCC, gastroesophageal junction adenocarcinoma and gastric cancer in combination with KN046. The drug candidate is administered intravenously. It is a fully-human monoclonal antibody (IgG2) against ALK-1.

The drug candidate was also under development for malignant pleural mesothelioma, refractory metastatic colorectal cancer, relapsed or refractory urothelial cancer, breast cancer, prostate cancer, and age related macular degeneration.

Kintor Pharmaceutical overview

Kintor Pharmaceutical (Kintor) is a clinical stage drug company. It is involved in discovering and developing novel small molecule therapeutics targeting cancer and other androgen receptor related diseases. The company’s lead product candidate Proxalutamide (GT0918), Pyrilutamide (KX-826), ALK-1 (GT90001), Destorsertib (GT0486), GT-1798F, GT20029 and others. It offers therapeutic drugs for various disease such as metastatic castration-resistant prostate cancer, hepatocellular carcinoma, gastric carcinoma, urothelial carcinoma, Leukaemia and other disease. Kintor is involved in discovering medicine and drugs for novel diseases such as COVID -19, prostate, breast, blood and liver cancers. In addition it also carries out research and development operations to discover treatment for alopecia and acne. It carters to clients across Taiwan, Hong Kong, the Us, Brazil, and China. The company runs its operations across Hong Kong, China, and the US. Kintor is headquartered in Suzhou, Jiangsu, China.

For a complete picture of Ascrinvacumab’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.